AI
ELGX

Accredited Investors’s Endologix Inc ELGX Stock Holding History

Accredited Investors’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$486K – 127
2017
Q2 		$486K Buy
+10,000
New +$589K 0.13% 54

Other funds holding ELGX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Accredited Investors's ELGX Position: Q3 2017 in Review

Accredited Investors sold out of Endologix Inc (ELGX) in Q3 2017, closing a stake of 10,000 shares — an estimated $486K sold.

Accredited Investors first reported a position in ELGX in Q2 2017 and held it in 1 quarter. The position peaked at $486K in Q2 2017. 106 funds tracked by Wall St. Rank hold ELGX as of Q3 2017.

  • Accredited Investors reported no remaining Endologix Inc position as of Q3 2017 after selling out during the quarter.
  • Accredited Investors sold 10,000 Endologix Inc shares in Q3 2017, an estimated $486K.
  • Accredited Investors first reported a position in Endologix Inc in Q2 2017 and held it in 1 quarter.
  • Accredited Investors's Endologix Inc position peaked at $486K in Q2 2017.
  • 106 funds tracked by Wall St. Rank held Endologix Inc as of Q3 2017.

Based on Accredited Investors's 13F filing for Q3 2017, filed 30 Oct 2017.